iRhythm Technologies (IRTC) Projected to Announce Earnings on Thursday

iRhythm Technologies (NASDAQ:IRTC) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $0.0155 per share and revenue of $222.23 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

iRhythm Technologies (NASDAQ:IRTC) last posted its earnings results on Thursday, August 6th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.62. iRhythm Technologies had a negative net margin of 1.69% and a positive return on equity of 10.11%. The business had revenue of $224.17 million for the quarter, compared to analyst estimates of $219.30 million. During the same period in the prior year, the company posted ($0.32) EPS. The company’s revenue for the quarter was up 20.1% on a year-over-year basis. On average, analysts expect iRhythm Technologies to post $0.54 EPS for the current fiscal year and $1.37 EPS for the next fiscal year.

iRhythm Technologies Price Performance

NASDAQ:IRTC opened at $126.17 on Tuesday. iRhythm Technologies has a 52 week low of $100.70 and a 52 week high of $192.47. The company has a quick ratio of 3.74, a current ratio of 3.86 and a debt-to-equity ratio of 3.50. The stock has a market capitalization of $4.16 billion, a PE ratio of 269.54 and a beta of 1.45. The stock’s 50-day moving average price is $114.99 and its 200-day moving average price is $122.63.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IRTC shares. Needham & Company LLC increased their price target on iRhythm Technologies from $192.00 to $194.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Truist Financial boosted their price objective on iRhythm Technologies from $160.00 to $168.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Stephens initiated coverage on iRhythm Technologies in a research note on Thursday, July 23rd. They set an “overweight” rating and a $160.00 target price for the company. Wells Fargo & Company decreased their target price on iRhythm Technologies from $168.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 6th. Finally, Wall Street Zen lowered iRhythm Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $174.50.

About iRhythm Technologies

iRhythm Technologies, Inc is a digital health company focused on the diagnosis and management of cardiac arrhythmias. The company provides ambulatory cardiac monitoring services that enable physicians to evaluate patients for conditions such as atrial fibrillation and other irregular heart rhythms.

Its principal offering is the Zio platform, which combines wearable electrocardiogram (ECG) monitoring devices with cloud-based data analysis and physician reports. Products in the platform include the Zio XT, an extended-wear monitor, and the Zio AT, which provides near-real-time monitoring capabilities.